VIE/BIIB (VIE/BIIB)

Vienna Stock Exchange: VIE/BIIB · EUR

€226

+4.05 (+1.8%)· Recorded snapshot

Market cap	33.1B
Revenue (ttm)	9.1B
Net income (ttm)	306M
EPS (ttm)	€2.09
P/E (trailing)	108.5x
P/E (forward)	16.8x
Volume	36

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 9.1B
Net income (ttm): 306M
EPS (ttm): €2.09
P/E (trailing): 108.5x
P/E (forward): 16.8x
Market cap: 33.1B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-30 13:30 UTC

Forward P/E16.8

P25 14.3P50 18.7P75 25.4

Trailing P/E108.5

P25 20.4P50 26.7P75 39.7

ROE1.9

P25 4.8P50 10.6P75 20.1

ROIC7.4

P25 5.8P50 9.5P75 18.2

Benchmarks · 1M

All VIE/BIIB indicators

Market & fundamental data

Available fields

228

Groups with data

Currency

USD

Showing 228 of 228 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	EUR
Country	United States
Country code	AT
Earnings date	2026-10-28
Employees	7,500
Employees change	-105
Employees growth	-1.38%
Enterprise value	EUR 38.9B
Exchange	Vienna Stock Exchange
Financial currency	USD
Financial report date	2026-09-30
First seen	2026-05-10
Fiscal year end	December
Founded	1978
Industry	Drug Manufacturers - General
Is primary listing	No
ISIN number	US09062X1037
Last earnings date	2026-10-28
Last refreshed	2026-10-30
Market cap	EUR 33.1B
Next earnings date	2027-02-05
Price	EUR 226.45
Price currency	EUR
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-29
Symbol	vie/BIIB
Website	https://www.biogen.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	19.56x
Average P/E ratio (3Y)	27.63x
Average P/E ratio (5Y)	23.52x
Earnings yield	0.92%
EV/Earnings	127.04x
EV/EBIT	17.93x
EV/EBITDA	12.68x
EV/FCF	21.32x
EV/Sales	4.21x
FCF / EV yield	4.69%
FCF yield	5.52%
Forward P/E	16.81x
Graham number	73.37977
Graham upside	-67.6%
Lynch fair value	EUR 10.48
Lynch upside	-95.37%
P/(FCF - SBC) ratio	21.23x
P/(OCF - SBC) ratio	19.3x
P/B ratio	1.98x
P/E ratio	108.51x
P/FCF ratio	18.13x
P/OCF ratio	16.7x
P/S ratio	3.65x
Price/EBITDA ratio	11.37x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	23.5%
EBITDA margin	32.07%
Effective tax rate	21.93%
FCF margin	19.82%
Gross margin	75.77%
Operating margin	23.5%
Pretax margin	4.32%
Profit margin	3.37%
Profit per employee	EUR 40,801
Profitable years	22
Revenue per employee	EUR 1.2M
ROA	4.94%
ROA (5Y)	6.68%
ROCE	8.6%
ROE	1.87%
ROE (5Y)	13.26%
ROIC	7.36%
ROIC (5Y)	13.87%
SBC / revenue	2.94%
Tax / revenue	0.95%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-78.71%
EPS growth 10Y	-18.32%
EPS growth 3Y	-38.52%
EPS growth 5Y	-25.55%
EPS growth years	0
FCF growth	-10.14%
FCF growth (Q)	-51.04%
FCF growth (QoQ)	47.16%
FCF growth 3Y	24.95%
FCF growth 5Y	-0.67%
Gross profit growth	17.87%
Gross profit growth (Q)	5.59%
Gross profit growth 3Y	1.29%
Gross profit growth 5Y	-3.16%
Net income growth	-78.4%
Net income growth 3Y	-38.05%
Net income growth 5Y	-25.81%
Net income growth years	0
OCF growth	-8.42%
OCF growth (Q)	-49.64%
OCF growth (QoQ)	42.75%
OCF growth 10Y	-5.71%
OCF growth 3Y	18.23%
OCF growth 5Y	-1.59%
Operating income growth	-17.05%
Operating income growth (Q)	-12.43%
Operating income growth 3Y	5.41%
Operating income growth 5Y	-1.08%
Revenue growth	2.3%
Revenue growth (Q)	10.63%
Revenue growth (QoQ)	2.49%
Revenue growth 10Y	-1.03%
Revenue growth 3Y	1%
Revenue growth 5Y	-1.49%
Revenue growth quarters	3
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	EUR -155.3M
Depreciation and amortization	EUR 787.7M
EBIT	EUR 2.1B
EBITDA	EUR 2.9B
EPS	EUR 2.09
Financing cash flow	EUR 635.3M
Free cash flow	EUR 1.8B
Free cash flow minus SBC	EUR 1.6B
Gross profit	EUR 6.9B
Income taxes	EUR 85.9M
Investing cash flow	EUR -4.8B
Net borrowing	EUR 556.8M
Net cash flow	EUR -2.3B
Net income	EUR 306M
Operating cash flow minus SBC	EUR 1.7B
Operating income	EUR 2.1B
Revenue	EUR 9.1B
Stock-based compensation	EUR 266.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.89
Book value per share	EUR 112.74
Debt / EBITDA	2.28
Debt / equity	0.41
Debt / FCF	3.77
Goodwill	EUR 6.2B
Interest coverage	7.94
Long-term assets	EUR 21.5B
Long-term liabilities	EUR 8.1B
Net cash (debt)	EUR -5.7B
Net cash / market cap	-17.31%
Net debt / EBITDA	1.97
Net debt / equity	0.34
Net debt / FCF	3.14
Piotroski F-Score	5
Property, plant and equipment	EUR 2.8B
Shareholders' equity	EUR 16.7B
Tangible book value	EUR -1.3B
Tangible book value per share	EUR -8.64
Total assets	EUR 28.2B
Total cash	EUR 1.1B
Total debt	EUR 6.9B
Total liabilities	EUR 11.6B

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.34
Current assets	EUR 6.8B
Current liabilities	EUR 3.5B
Current ratio	1.95
Inventory turnover	1.13
Net working capital	EUR 2.4B
Quick ratio	0.95
Working capital	EUR 3.2B
Working capital turnover	1.94

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1.49%
Shareholder yield	-1.49%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	EUR 179.43
1D price change	1.82%
1M price change	12.35%
1M total return	12.35%
1W price change	1.59%
1W total return	1.59%
1Y price change	76.71%
1Y return CAGR	76.78%
1Y total return	76.71%
20-day SMA	EUR 209.53
200-day SMA	EUR 174.06
3M price change	27.28%
3M total return	27.28%
3Y price change	1%
3Y return CAGR	0.33%
3Y total return	1%
50-day SMA	EUR 198.16
50-day SMA vs 200-day SMA	50over200
52-week high	EUR 230.20
52-week high date	2026-10-28
52-week low	EUR 120.90
52-week low date	2025-10-30
5Y price change	0.42%
5Y return CAGR	0.08%
5Y total return	0.42%
6M price change	44.64%
6M total return	44.64%
All-time high	EUR 348.10
All-time high date	2021-06-10
All-time low	EUR 98.96
All-time low date	2025-04-09
Average true range (ATR)	EUR 5.10
Average volume	8.3
Change from 52-week high	-1.63%
Change from 52-week low	87.3%
Change from all-time high	-34.95%
Change from all-time low	128.83%
Change from open	3.21%
Day's gap	-1.35%
Dollar volume	EUR 8,152
High price	EUR 226.45
Low price	EUR 219.40
Monthly RSI	67.58
Open price	EUR 219.40
Position in 52-week range	100%
Previous close	EUR 222.40
Price vs 150-day SMA	26.2%
Price vs 20-day SMA	8.07%
Price vs 200-day SMA	30.1%
Price vs 50-day SMA	14.28%
Relative volume	4.34
RSI	68.37
Sharpe ratio	1.79
Sharpe ratio (3Y)	-0.02
Sharpe ratio (5Y)	0.02
Sortino ratio	2.92
Sortino ratio (3Y)	0.17
Sortino ratio (5Y)	0.23
Volume	36
Weekly RSI	79.19
YTD price change	50.72%
YTD total return	50.72%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	147.2M
Shares change (QoQ)	-0.61%
Shares change (YoY)	1.49%
Shares held by insiders	0.21%
Shares held by institutions	97.69%
Short ratio	5.3 days

Deeper analysis on VIE/BIIB

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this VIE/BIIB report

Is a complete VIE/BIIB research report available?

No complete published report is available for vie/BIIB (VIE/BIIB) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

VIE/BIIB (VIE/BIIB)

Price

Financial snapshot

Fair-value bridge

Latest news · VIE/BIIB

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All VIE/BIIB indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on VIE/BIIB

Frequently asked questions